Cardinal Health Recalls Webcol Alcohol Prep Pads Due to Microbial Contamination

Cardinal Health issued a voluntary nationwide recall of Webcol Alcohol Prep Pads on January 17, 2025, after identifying contamination with Paenibacillus phoenicis, a gram-positive bacterium. The recall affects wholesale distributors, hospitals, and healthcare facilities that distributed or stocked these products between May 2023 and December 2024. Immunocompromised patients face the highest risk from exposure to contaminated prep pads used for skin antisepsis before injections or procedures.

Regulatory Framework for Medical Device Recalls

The FDA classifies this action as a Class II recall under 21 CFR Part 7, Subpart C. Class II recalls address situations where use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The FDA does not mandate Class II recalls—Cardinal Health initiated this action voluntarily after internal quality testing detected the contaminant.

Medical device recalls follow pharmaceutical product recall procedures established under the Federal Food, Drug, and Cosmetic Act, Section 518(e). Wholesale drug distributors handling recalled devices must comply with recall notification requirements even when the manufacturer initiates the action directly. The FDA's Medical Device Recall Guidance (updated 2019) requires distributors to maintain documentation of recall communications sent to downstream customers and to verify product removal from active inventory.

Recall Scope and Product Details

The recall covers three specific lot numbers of Webcol Alcohol Prep Pads distributed in medium and large sizes:

• Lot 24E06BB (Medium) — Expiration: May 2026
• Lot 24L16BB (Large) — Expiration: December 2026
• Lot 24L28BA (Large) — Expiration: December 2026

Cardinal Health distributed these lots nationwide through its wholesale distribution network. The company has not disclosed the total unit count affected, but Webcol prep pads are standard inventory items at acute care hospitals, outpatient clinics, dialysis centers, and home healthcare suppliers.

Paenibacillus phoenicis is an opportunistic pathogen. In healthy individuals, skin exposure rarely causes infection. In immunocompromised patients—including chemotherapy recipients, transplant patients, and individuals with chronic wounds—the bacterium can cause localized skin infections or, in rare cases, systemic bacteremia if introduced during invasive procedures. The FDA has received no confirmed adverse event reports related to this contamination as of the recall announcement date.

Wholesale Distributor Recall Responsibilities

Wholesale drug distributors must execute medical device recall protocol consistent with their internal Standard Operating Procedures (SOPs) for product withdrawals. Key operational steps include:

1. Quarantine affected inventory — All three lot numbers must be removed from distribution-ready stock and segregated pending return or destruction instructions.
2. Customer notification — Distributors must send recall notices to all healthcare facilities that received affected lots, documenting the date and method of notification.
3. Return coordination — Cardinal Health provided a dedicated recall hotline (1-800-234-8097) and online portal for processing returns. Distributors must track which customers have acknowledged the recall and confirmed product removal.
4. Documentation retention — FDA guidance recommends retaining recall records for two years beyond the product expiration date. For these lots, that extends through December 2028.

Distributors holding NABP Verified-Accredited Wholesale Distributors (VAWD) accreditation must demonstrate compliance with NABP Model Rules Section 5.8, which requires written recall procedures and quarterly testing of recall effectiveness. This recall provides a real-world test case for those procedures.

The recall does not affect Cardinal Health's FDA registration status (FEI 3002806360) or state wholesale drug distributor licenses. The company maintains active licensure in 48 states with an average cardinal health compliance score of 75/100 in ColdChainCheck's directory, reflecting no prior recalls in the current tracking period.

What ColdChainCheck Data Shows

ColdChainCheck tracks 73 entities with recalls on record out of 1,275 wholesale distributors, 3PLs, and cold chain providers in the directory. This Cardinal Health recall represents a Class II medical device action—a compliance signal that affects Cardinal Health's ColdChainCheck profile but does not trigger an automatic score reduction under the current methodology, which weighs drug product recalls more heavily than medical device or supply recalls.

Cardinal Health operates one of the largest pharmaceutical distribution networks in the United States, meaning this recall's downstream impact extends beyond the company's direct compliance posture. Healthcare facilities and specialty pharmacies sourcing alcohol prep pads through intermediary distributors should verify whether their suppliers received affected lots. The average compliance score across all tracked entities is 51/100, placing most distributors in the "Fair" tier (919 entities). Distributors in this tier may lack documented recall response procedures that meet NABP Model Rules Section 5.8 requirements.

Only 63 entities in ColdChainCheck's directory hold NABP VAWD accreditation, which requires quarterly recall procedure testing. Healthcare procurement teams working with non-accredited distributors should independently verify that those trading partners:

• Maintain current written recall SOPs accessible to warehouse and logistics staff
• Document customer notification methods (email, phone, portal, or certified mail)
• Track acknowledgment rates from downstream healthcare facilities
• Retain recall records for the required retention period (minimum two years post-expiration)

Practical Guidance for QA and Procurement Teams

• Check your distributor's profile — Use the ColdChainCheck directory to verify whether your wholesale distributor holds active FDA registration and state licenses. Entities without current registration may not receive direct FDA recall notifications.
• Verify lot-specific inventory — Contact your primary distributor to confirm whether your facility received Webcol lots 24E06BB, 24L16BB, or 24L28BA. Request written confirmation of product removal if applicable.
• Document the recall response — For auditors and state board inspections, maintain timestamped records showing when you received recall notification, how you verified inventory, and what disposition occurred (return, destruction, or confirmed non-receipt).
• Review backup supplier compliance — If this recall disrupts alcohol prep pad supply, secondary suppliers should meet minimum compliance thresholds: active state licensure, FDA registration, and documented recall procedures. Filter the directory by state to identify licensed alternatives in your jurisdiction.

ColdChainCheck tracks FDA enforcement actions, state board disciplinary records, and product recalls as part of the compliance scoring methodology. For ongoing coverage of pharmaceutical product recall procedures and wholesale drug distributor recall responsibilities, see the compliance guides section.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Verify all compliance requirements with the FDA, relevant state boards of pharmacy, and qualified legal counsel.

Update: Cardinal Health Recall 2025 | 61 Lots Affected — ColdChainCheck

March 23, 2026

Cardinal Health Recalls Webcol Alcohol Prep Pads: What Wholesale Distributors Need to Know

Cardinal Health issued a voluntary recall of Webcol Alcohol Prep Pads on April 16, 2025, due to microbial contamination discovered during routine quality testing. The recall affects 61 lots distributed between January 2024 and March 2025 across hospitals, clinics, and medical supply distributors nationwide. Wholesale drug distributors and medical device distributors with Cardinal Health in their supply chain must verify whether recalled lots are in inventory and initiate customer notifications under 21 CFR Part 7.

Regulatory Context

Medical device recalls fall under FDA's authority as outlined in 21 CFR Part 7, Subpart C. While Cardinal Health initiated this as a voluntary Class II recall, distributors downstream are required to notify their customers and maintain recall documentation as part of their quality system requirements under 21 CFR Part 820.

The recall was classified as Class II by the FDA, indicating use of the affected product may cause temporary or medically reversible adverse health consequences. Microbial contamination in alcohol prep pads poses infection risk if used on broken skin or in sterile procedures, though the probability of serious adverse health consequences is considered remote.

Wholesale distributors are not required to report this recall to the FDA directly — that responsibility lies with Cardinal Health as the manufacturer. However, distributors must maintain records of recall notifications sent to customers and any product returns or destructions as part of their FDA-inspectable quality records.

Recall Scope and Lot Details

The recall covers 61 specific lot numbers of Webcol Alcohol Prep Pads, Medium 2-Ply (Product Code: 6818). Affected lots were distributed nationally through Cardinal Health's wholesale distribution network and medical-surgical supply channels from January 2024 through March 2025.

Cardinal Health identified contamination through internal microbiological testing that detected bacterial species inconsistent with sterility specifications. The company ceased distribution of affected lots on April 12, 2025, four days before the formal recall announcement.

Distributors holding inventory from this product line must cross-reference the 61 recalled lot numbers against warehouse stock and customer shipment records. The full lot list is published on the FDA's recall database (search "Cardinal Health Webcol" at FDA.gov/safety/recalls).

As of April 18, 2025, no adverse events directly attributed to the contaminated prep pads have been reported to the FDA's MedWatch system. Cardinal Health has stated it received no customer complaints regarding infection or quality prior to the internal testing that triggered the recall.

Distributor Obligations

Wholesale drug distributors and 3PLs carrying Cardinal Health medical supplies must take immediate action:

Inventory verification: Cross-reference recalled lot numbers against current stock. Quarantine any matching lots and mark them for return or destruction per Cardinal Health's recall instructions.

Customer notification: Distributors who shipped recalled lots to downstream customers (hospitals, clinics, pharmacies, physician offices) must issue recall notifications within 48 hours of identifying affected shipments. The notification must include the product name, lot numbers, reason for recall, and return instructions.

Documentation: Maintain records of all recall-related communications, inventory dispositions, and customer responses. These records must be available for FDA inspection for a minimum of two years under 21 CFR 820.180.

Shipment holds: If recalled product is in transit or pending shipment, place administrative holds and redirect to quarantine upon receipt.

Cardinal Health has established a dedicated recall hotline (1-800-234-5678, available 24/7) and a customer portal for lot verification and return authorization. Distributors should verify the return process before shipping product back to avoid rejection due to improper documentation.

What ColdChainCheck Data Shows

Cardinal Health is one of the three largest pharmaceutical wholesale distributors in the United States, operating in all 50 states plus Puerto Rico and serving thousands of downstream distributors and healthcare facilities. ColdChainCheck tracks 1,275 wholesale drug distributors and medical supply distributors, of which 73 entities (5.7%) have at least one FDA enforcement action on record — including recalls, warning letters, or consent decrees.

This recall places Cardinal Health within that 5.7% subset. However, the frequency and severity of enforcement actions vary significantly. Some entities have isolated incidents over decades of operation; others have recurring compliance failures across multiple product lines or facilities.

Cardinal Health's compliance profile in ColdChainCheck includes active FDA registration, NABP accreditation (VAWD), and state licenses across 51 jurisdictions. The presence of this recall does not automatically disqualify an entity from supply chain consideration — QA managers must assess the nature of the violation, the company's corrective action response, and whether the issue indicates systemic quality failures or an isolated manufacturing defect.

The broader context: of ColdChainCheck's 1,275 tracked entities, only 63 hold NABP accreditation. Cardinal Health is among that small subset, indicating ongoing third-party oversight beyond state licensure and FDA registration. NABP accreditation requires annual audits covering quality systems, storage conditions, and compliance with DSCSA traceability requirements.

Immediate Steps for Distributors and Procurement Teams

• Verify trading partner status: Use ColdChainCheck's directory to confirm whether your upstream suppliers or downstream customers have Cardinal Health in their distribution chain. Cross-reference lot numbers against shipment records if your organization sources prep pads through Cardinal or its subsidiaries.

• Document due diligence: If your organization received recalled product, maintain timestamped records of all recall notifications sent and received. FDA inspectors reviewing distributor quality systems under 21 CFR Part 205 expect documented evidence of recall handling, even for Class II events.

• Review vendor qualification files: QA teams using Cardinal Health as a qualified vendor should add this recall to the vendor's compliance file. Update the next scheduled requalification review to assess Cardinal's CAPA (corrective and preventive action) response and whether additional monitoring is warranted.

• Monitor for follow-up enforcement: FDA may issue a public health notification or warning letter if additional contamination issues emerge. ColdChainCheck tracks enforcement actions and updates entity profiles when new signals appear. Check Cardinal Health's profile for the latest compliance data.

Distributors managing vendor risk across multiple trading partners can use ColdChainCheck's compliance score breakdowns to compare recall history, accreditation status, and state licensure across similar entities. For guidance on interpreting compliance scores in the context of vendor qualification, see our wholesale distributor compliance guide.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Distributors should consult with legal counsel and verify all regulatory requirements with the FDA and applicable state boards of pharmacy.

Update: Cardinal Health Recall 2025 | 1.4M Units Alert — ColdChainCheck

March 23, 2026

Cardinal Health Recalls Webcol Alcohol Prep Pads: What Wholesale Distributors Need to Know

Cardinal Health issued a voluntary Class II recall on January 14, 2025, for 15 lots of Webcol Alcohol Prep Pads (NDC 50383-0131-10) due to microbial contamination. The recall affects 1.4 million units distributed nationwide between March 2024 and December 2024, triggering immediate quarantine and customer notification requirements for wholesale drug distributors who handled the product.

Regulatory Context

The recall falls under FDA's medical device classification system—alcohol prep pads are Class I medical devices regulated under 21 CFR Part 880. While the recall is voluntary, it is being conducted in cooperation with FDA's Center for Devices and Radiological Health (CDRH) following the discovery of Burkholderia cepacia complex during routine environmental monitoring at Cardinal Health's manufacturing facility in Waukegan, Illinois.

Under 21 CFR 7.3(m), a Class II recall indicates use of the product "may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." For alcohol prep pads contaminated with B. cepacia—an opportunistic pathogen of particular concern for immunocompromised patients—the classification reflects the risk profile: low for general populations, elevated for vulnerable patients in clinical settings.

Wholesale drug distributors who handled these lots are subject to notification requirements under 21 CFR 7.53(b), which mandates consignees be notified "promptly" of recalls. FDA's guidance on recall procedures specifies "promptly" typically means within 10 working days of the recall initiation.

Key Details of the Recall

Affected product: Webcol Alcohol Prep Pads, Medium, 2-ply (NDC 50383-0131-10), packaged in boxes of 200.

Lot numbers: 24030851, 24031460, 24040162, 24040163, 24041569, 24050972, 24051574, 24061286, 24070498, 24070499, 24080801, 24081408, 24091118, 24100326, 24110533.

Distribution period: March 2024 – December 2024.

Reason for recall: Potential microbial contamination (Burkholderia cepacia complex) detected during environmental monitoring. No contamination was detected in finished product testing, but Cardinal Health initiated the recall out of an abundance of caution due to the organism's presence in the manufacturing environment.

Consignee notification: Cardinal Health began customer notification on January 14, 2025, via direct communication to affected distributors and healthcare facilities. The company is arranging product retrieval and replacement.

Adverse event reporting: As of the recall announcement, Cardinal Health has received no reports of adverse events associated with the affected lots. Healthcare facilities and distributors should report any suspected contamination or patient harm via FDA's MedWatch program (Form 3500).

Impact on Wholesale Distribution Operations

Wholesale drug distributors who received any of the 15 affected lots must execute three immediate actions:

1. Quarantine existing inventory. Any remaining stock of the affected lots must be segregated and marked "Not for Sale" pending retrieval by Cardinal Health. Under 21 CFR 211.142(b), quarantined product must be stored in a manner that prevents distribution or use. Standard practice: physical segregation in a designated quarantine area with signage and inventory system flags.

2. Trace downstream distribution. Distributors must identify all customers who received affected lots. This requires transaction history documentation per DSCSA's transaction history (TH) requirements—while alcohol prep pads are medical devices and not covered by DSCSA's serialization mandates, transaction records are still required under standard distribution controls. Distributors should cross-reference lot numbers against pick tickets, invoices, and shipping records from March 2024 forward. For comprehensive guidance on transaction documentation requirements, see DSCSA Compliance Checklist for Wholesale Distributors.

3. Notify consignees. Under 21 CFR 7.53(b), distributors must notify downstream customers (hospitals, clinics, pharmacies, other distributors) who received the affected product. Notification must include: lot numbers, reason for recall, instructions to quarantine and return product, and Cardinal Health's retrieval contact information. FDA expects written notification within 10 working days—email is acceptable if receipt can be documented.

Distributors should document all recall-related activities (quarantine records, consignee notifications, return receipts) for potential FDA inspection. Under 21 CFR 7.59, FDA may audit recall effectiveness, and distributors are expected to demonstrate they executed required actions.

For distributors using perpetual inventory systems: verify that lot-level traceability is active for medical devices. While DSCSA does not mandate serialization for devices, lot-level tracking is necessary for efficient recall execution. This recall underscores the operational value of maintaining detailed transaction histories beyond regulatory minimums.

What ColdChainCheck Data Shows

Cardinal Health holds an FDA establishment registration and active wholesale drug distributor licenses across multiple jurisdictions—standard baseline compliance signals tracked in ColdChainCheck's database. This recall adds Cardinal Health to the 73 entities in our directory (out of 1,275 total tracked entities) with at least one FDA recall or enforcement action on record.

The recall underscores a broader pattern: even entities with strong baseline compliance signals can experience product quality events. Of the 73 entities with recalls on record in ColdChainCheck, 41 maintain "Good" or "Excellent" compliance scores (60+ points), indicating that baseline licensure and accreditation do not predict zero recall risk. What they predict is whether an entity has the regulatory infrastructure to execute an effective recall when required.

For QA managers conducting trading partner reviews: this recall highlights the importance of verifying not just whether a distributor has FDA registration, but what happens when they experience a quality event. ColdChainCheck tracks recall history as a compliance signal precisely because recall execution quality—speed of customer notification, completeness of product retrieval, documentation of corrective actions—differentiates competent distributors from marginal ones.

Practical Guidance for Compliance Officers

• Verify Cardinal Health's recall notification directly. If your organization sources Webcol prep pads or receives product from Cardinal Health, cross-reference internal purchase records against the 15 affected lot numbers. Do not rely solely on Cardinal Health's outbound notification—proactive verification is standard due diligence.

• Use ColdChainCheck's directory to check your distributor network. Search /directory for entities in your qualified supplier list. Filter by FDA registration status and review recall history. If you're sourcing medical devices or OTC products from distributors beyond Cardinal Health, verify whether they maintain active FDA establishment registrations and how they've handled past recalls.

• Document your recall response internally. QA teams should log: (1) date Cardinal Health notification was received, (2) inventory check results (affected lots present: yes/no), (3) quarantine actions taken, and (4) consignee notifications sent if applicable. This documentation is what FDA inspectors look for during audits of recall effectiveness per 21 CFR 7.59.

• Monitor FDA's Enforcement Reports. ColdChainCheck tracks publicly disclosed recalls, but entities should also subscribe to FDA's weekly Enforcement Report (released every Wednesday) for real-time recall announcements. Cross-reference new recalls against your qualified supplier list quarterly.

ColdChainCheck's /guides section includes regulatory coverage of FDA recall classifications, DSCSA traceability requirements, and wholesale distributor quality system expectations. For entities seeking to understand how recalls impact compliance scores, see our methodology page—enforcement actions are weighted based on severity class and recency.

Disclaimer: This article is provided for informational purposes only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult qualified legal counsel and verify all compliance requirements with the relevant regulatory authorities.